Bioengineering strategies for inducing tolerance in autoimmune diabetes

Type 1 diabetes is an autoimmune disease marked by the destruction of insulin-producing beta cells in the pancreatic islets. Strategies to delay onset or prevent the autoimmune recognition of beta cell antigens or T cell-mediated killing of beta cells have mainly focused on systemic immunomodulation and antigen-specific immunotherapy. To bridge the fields of type 1 diabetes immunology and biomaterials engineering, this article will review recent trends in the etiology of type 1 diabetes immunopathology and will focus on the contributions of emerging bioengineered strategies in the fight against beta cell autoimmunity in type 1 diabetes. (C) 2017 Elsevier B.V. All rights reserved.


Published in:
Advanced Drug Delivery Reviews, 114, 256-265
Year:
2017
Publisher:
Amsterdam, Elsevier Science Bv
ISSN:
0169-409X
Keywords:
Laboratories:




 Record created 2017-10-09, last modified 2018-09-13


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)